Immunocore Holdings Ltd (IMCR)vsVertex Pharmaceuticals Inc (VRTX)
IMCR
Immunocore Holdings Ltd
$32.60
-2.92%
HEALTHCARE · Cap: $1.82B
VRTX
Vertex Pharmaceuticals Inc
$515.44
+0.17%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2822% more annual revenue ($12.59B vs $430.77M). VRTX leads profitability with a 35.0% profit margin vs -4.2%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
IMCR
Hold37
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMCR.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$515.44
$448.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 150.0% YoY
18.3% revenue growth
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
ROE of -7.1% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCR
The strongest argument for IMCR centers on EPS Growth, Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : IMCR
The primary concerns for IMCR are Market Cap, Debt/Equity, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IMCR profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
IMCR carries more volatility with a beta of 0.74 — expect wider price swings.
IMCR is growing revenue faster at 18.3% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 37/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immunocore Holdings Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?